Back to stories
Models

OpenAI Releases GPT-5.3 Instant: 27% Fewer Hallucinations and a Less 'Cringe' Personality

Michael Ouroumis2 min read
OpenAI Releases GPT-5.3 Instant: 27% Fewer Hallucinations and a Less 'Cringe' Personality

OpenAI has shipped GPT-5.3 Instant, a meaningful update to ChatGPT's most widely used model that focuses on getting the basics right rather than chasing new capabilities. The update is now rolling out to all ChatGPT users and is available to developers in the API as gpt-5.3-chat-latest.

Fewer Hallucinations

The headline improvement is accuracy. According to OpenAI's internal benchmarks, GPT-5.3 Instant reduces hallucination rates by 26.8 percent when using web search and 19.7 percent when relying solely on internal knowledge. For users who depend on ChatGPT for research, writing, or coding assistance, this represents a tangible improvement in trustworthiness.

The gains come from a combination of improved retrieval-augmented generation, better calibration of confidence levels, and refined post-training techniques that teach the model to say "I don't know" rather than fabricate plausible-sounding answers.

The Anti-Cringe Update

OpenAI acknowledged user feedback that GPT-5.2 Instant could come across as overly cautious, preachy, or performatively enthusiastic. The new model significantly reduces unnecessary refusals — cases where the model would decline to answer perfectly safe questions — and tones down what users have described as "cringe" behavior: moralizing preambles, excessive caveats, and artificially cheerful language.

The result is a model that gets to the point faster and feels more like a capable assistant than a cautious committee.

Web Search Improvements

GPT-5.3 Instant also delivers richer and better-contextualized results when searching the web. OpenAI says the model is better at synthesizing information from multiple sources and presenting it in a coherent narrative, reducing the "dead ends" that sometimes occurred when previous versions struggled to find or interpret relevant web content.

Developer and API Access

For developers, GPT-5.3 Instant is available immediately through the API. The previous GPT-5.2 Instant will remain accessible as a legacy option for paid users until June 3, 2026, providing a transition window for applications that depend on specific model behavior.

What Comes Next

Barely an hour after announcing GPT-5.3 Instant, OpenAI teased GPT-5.4 — suggesting the company is maintaining an aggressive release cadence. While details on GPT-5.4 remain sparse, early hints point to enhanced reasoning capabilities under a new "Thinking" mode.

For now, GPT-5.3 Instant represents a welcome shift in priorities: instead of pushing the frontier, OpenAI is polishing the experience for the hundreds of millions of people who use ChatGPT every day.

Learn AI for Free — FreeAcademy.ai

Take "AI Essentials: Understanding AI in 2026" — a free course with certificate to master the skills behind this story.

More in Models

Moonshot Kimi K2.6 lands open-source, scales to 300 sub-agents and 4,000 coordinated steps
Models

Moonshot Kimi K2.6 lands open-source, scales to 300 sub-agents and 4,000 coordinated steps

Moonshot AI shipped Kimi K2.6 as a generally available open-source model on April 20, posting 58.6 on SWE-Bench Pro — ahead of GPT-5.4 and Claude Opus 4.6 — while scaling agent swarms to 300 sub-agents and 4,000 coordinated steps.

9 hours ago3 min read
OpenAI's 'Spud' Caught Live in API Testing, Polymarket Jumps to 81% for April 23 Launch
Models

OpenAI's 'Spud' Caught Live in API Testing, Polymarket Jumps to 81% for April 23 Launch

API monitors detected OpenAI's next frontier model — codenamed Spud — running in production-scale testing on April 19, sending Polymarket traders to an 81% implied probability of a public launch on April 23.

1 day ago2 min read
OpenAI Launches GPT-Rosalind, Its First Domain-Specific Model Built for Life Sciences
Models

OpenAI Launches GPT-Rosalind, Its First Domain-Specific Model Built for Life Sciences

OpenAI debuts GPT-Rosalind, a specialized AI model for biology, drug discovery, and genomics, with launch partners including Amgen, Moderna, and Los Alamos National Laboratory.

4 days ago2 min read